Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with
diabetes and therefore managing cardiovascular (CV) risk is a critical component of …

Cardiovascular disease is the predominant cause of death in diabetic patients, and yet the
cardiovascular benefits of traditional drug treatments for hyperglycemia have been elusive …

Glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4)
inhibitors represent 2 distinct classes of incretin-based therapies used for the treatment of …

The global epidemic of diabetes mellitus (∼ 95% type 2 diabetes) has been fueled by a
parallel increase in obesity and overweight. Together, these metabolic disease epidemics …

Background GLP-1 is an incretine hormone which gets secreted from intestinal L-cells in
response to nutritional stimuli leading to pancreatic insulin secretion and suppression of …

Background—The glucagon-like peptide 1 receptor (GLP-1R) is believed to mediate
glucoregulatory and cardiovascular effects of the incretin hormone GLP-1 (7-36)(GLP-1) …

The health burden of type 2 diabetes mellitus continues to increase worldwide. A substantial
portion of this burden is due to the development of cardiovascular disease in patients with …

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone whose glucose‐dependent
insulinotropic actions have been harnessed as a novel therapy for glycaemic control in type …

Type 2 diabetes mellitus is acknowledged as a major risk factor for the development of
cardiovascular disease (CVD). Advancing treatment options for person with diabetes …

The prevalence of type 2 diabetes mellitus, which is directly associated with
overweight/obesity and increased cardiovascular disease risk, is projected to continue to …